Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes

被引：10
作者：
Schmid, C. [2 ]
Krayenbuhl, P. [3 ]
Wiesli, P. [1 ]
机构：
[1] Kantonsspital, Med Klin, CH-8500 Frauenfeld, Switzerland
[2] Univ Zurich Hosp, Dept Internal Med, Div Endocrinol & Diabet, Zurich, Switzerland
[3] Univ Zurich Hosp, Dept Internal Med, Med Policlin, Zurich, Switzerland
来源：
DIABETOLOGIA | 2009年 / 52卷 / 12期
关键词：
Hyperinsulinaemia; Insulin dose requirement; Long-acting insulin analogues; Obesity; Type; 2; diabetes; TO-TARGET TRIAL; NPH INSULIN; THERAPY; GLARGINE; DETEMIR;
D O I：
10.1007/s00125-009-1534-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2668 / 2669
页数：2
相关论文
共 50 条
[31]   A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa [J].
Verryn, Mark T. ;
Cleary, Susan .
COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2025, 23 (01)
[32]   Insulin degludec: overview of a novel ultra long-acting basal insulin [J].
Gough, S. C. L. ;
Harris, S. ;
Woo, V. ;
Davies, M. .
DIABETES OBESITY & METABOLISM, 2013, 15 (04) :301-309
[33]   Budget Impact of Long-Acting Insulin Analogues: The Case in Brazil [J].
Laranjeira, Fernanda O. ;
da Silva, Everton Nunes ;
Pereira, Mauricio G. .
PLOS ONE, 2016, 11 (12)
[34]   Willingness to Pay for Improvements in Chronic Long-Acting Insulin Therapy in Individuals With Type 1 or Type 2 Diabetes Mellitus [J].
Lloyd, Andrew ;
Nafees, Beenish ;
Barnett, Anthony H. ;
Heller, Simon ;
Ploug, Uffe J. ;
Lammert, Morten ;
Bogelund, Mette .
CLINICAL THERAPEUTICS, 2011, 33 (09) :1258-1267
[35]   Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin [J].
Bradley, Marie C. ;
Chillarige, Yoganand ;
Lee, Hana ;
Wu, Xiyuan ;
Parulekar, Shruti ;
Muthuri, Stella ;
Wernecke, Michael ;
MaCurdy, Thomas E. ;
Kelman, Jeffrey A. ;
Graham, David J. .
JAMA INTERNAL MEDICINE, 2021, 181 (05) :598-607
[36]   Effect of dulaglutide and long-acting insulin combination therapy in patients with type 2 diabetes: a retrospective observational study [J].
Ito, Kohei ;
Satoh, Shinobu ;
Kondo, Yoshinobu ;
Tamura, Haruka ;
Hasebe, Masanori ;
Terauchi, Yasuo .
DIABETOLOGY INTERNATIONAL, 2023, 14 (01) :51-57
[37]   Intensification of Diabetes Treatment with Long-Acting Insulin Shows no Benefit over Other Diabetes Treatment [J].
Wainstein, Julio ;
Leibovitz, Eyal ;
Segal, Tuvia ;
Gavish, Dov .
ISRAEL MEDICAL ASSOCIATION JOURNAL, 2011, 13 (09) :537-541
[38]   Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine [J].
Davies, M. ;
Khunti, K. .
DIABETES OBESITY & METABOLISM, 2008, 10 :42-49
[39]   Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes [J].
Esposito, Katherine ;
Giugliano, Dario .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (02) :209-221
[40]   Quality of life and treatment satisfaction in patients being treated with long-acting insulin analogues: systematic review [J].
Hagenmeyer, E. G. ;
Schaedlich, P. K. ;
Koester, A. D. ;
Dippel, F-W. ;
Haeussler, B. .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2009, 134 (12) :565-570
12345